Autolus

Q2 2026 Financial Results and Business Updates

August 11, 2026

For Investor communication only. Not for use in product promotion. Not for further distribution.

Disclaimer

These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” and “believes.” These statements include, but are not limited to: statements regarding Autolus’ development and commercialization of its product candidates; Autolus' manufacturing, sales and marketing plans for AUCATZYL, including expectations regarding the commercial launch in the United States and the ability to reach patients in a timely manner; the amount and timing of milestone payments under Autolus' collaboration and license agreements; and future development plans of obe-cel, including the timing or likelihood of expansion into additional markets or geographies and related regulatory approvals. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: Autolus' ability to maintain regulatory approval of AUCATZYL; its ability to execute its commercialization strategy for AUCATZYL; its ability to develop, manufacture and commercialize its other product candidates and the timing or likelihood of expansion of AUCATZYL into additional markets or geographies; Autolus' ability to maintain a commercial infrastructure and to successfully launch, market and sell AUCATZYL; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or future regulatory approval; the labelling for AUCATZYL/obe-cel in any future indication or patient population, if approved; the potential for payors to delay, limit or deny coverage for AUCATZYL; Autolus' ability to obtain, maintain and enforce intellectual property protection for AUCATZYL or any product candidates it is developing; the results of clinical trials are not always being predictive of future results; the cost, timing and results of clinical trials; that many product candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; and possible safety and efficacy concerns. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Autolus’ actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in Autolus' Annual Report on Form 10-K filed with the Securities and Exchange Commission, or the SEC, on March 27, 2026, as well as discussions of potential risks, uncertainties, and other important factors in Autolus’ subsequent filings with the Securities and Exchange Commission. All information in this presentation is as of the date of the presentation, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing the Company’s views as of any date subsequent to the date of this presentation.

Agenda

- Welcome and Introduction: Amanda Cray, ED, Investor Relations & External Communications
- Operational Highlights: Dr. Christian Itin, CEO
- Financial Results: Rob Dolski, CFO
- Upcoming Milestones and Conclusion: Dr. Christian Itin, CEO
- Q&A: Dr. Christian Itin and Rob Dolski

Strong AUCATZYL® sales growth in Q2 2026

AUCATZYL Global Net Product Revenue

Q2 2026	1H 2026
$45.7 million	$71.9 million
+119% year-over-year	+140% year-over-year

Growth Drivers

- Penetration into US market deepening with positive physician experience in existing authorized treatment centers
- Expansion into new treatment centers in the US & improving distribution of registrations across the ATC footprint
- Supported by ROCCA consortium real-world data presentations
- Early in launch, UK showing strong adoption and treatment center expansion

82 U.S. Authorized Treatment Centers

Autolus™ Assist

Executing to plan with momentum in 2026

2026 Expectations & Financial Guidance

FY 2026 Net Product Revenue

Increased from **$120-$135** million

Now expect **$140 - $150 million**

Gross Margin

Achieved: Shift to **positive gross margin in 2026** based on increasing volumes and improved manufacturing plant operation

Commercial Expansion

Achieved: Increase commercial footprint in the US to more than **80** treatment centers

Path to profitability in the r/r B-ALL business

Optimizing the operating model and driving cost efficiency

Increasing volumes and operational efficiency initiatives producing gross margin improvements

We are here

- ✓ Launch: Establish consistent and high-quality product supply and service
- Optimization: Improve efficiency and increase volumes to drive margins
- Peak: expect gross profit margin of 65-70%

Gross Margin %*



Expect continued improvement with volumes and cost efficiencies

*Gross Margin percentage represents gross margin (net product revenue less cost of sales) divided by net product revenue

Pipeline-in-a-product: expanding obe-cel's potential beyond adult B-ALL

Anticipated news flow and data catalysts for ongoing pipeline programs

	Timing	Program	Update	Indication	Trial
●	End of 2026	Obe-cel	Longer-term follow up data	Systemic Lupus (SLE)	CARLYSLE Phase 1
●	End of 2026	AUTO 8	Initial data in ~10 patients	AL Amyloidosis	ALARIC Phase 1
●	Q1 2027	Obe-cel	Preliminary results	Progressive Multiple Sclerosis	BOBCAT Phase 1
●	2H 2027	Obe-cel	Additional data with longer follow up	Progressive Multiple Sclerosis	BOBCAT Phase 1
●	End of 2027	Obe-cel	Phase 2 data	Pediatric r/r B-ALL	CATULUS Phase 1/2
●	2028	Obe-cel	Phase 2 data	Lupus Nephritis (LN)	LUMINA Phase 2

● Oncology ● Autoimmune / B Cell Mediated Disease

Upcoming data update: BOBCAT Trial in Progressive MS

Patient and physician interest is high; trial enrollment continues on track

Q1 2027

Preliminary Phase 1 Data: Targeting ACTRIMS

- Total 12 patients
  - Safety
  - PK/PD
  - Biomarker data

2H 2027

Full Phase 1 Data

- Total 18 patients
  - Clinical response and longer-term follow up
  - Imaging data
  - Expanded safety, PK/PD & biomarker data
  - Potential path for next development and regulatory activities

Determining clinical efficacy in MS, as measured by EDSS or other clinical assessments, **requires approximately 12 months of follow-up to understand response** due to variability in symptoms and disease activity

Financial Results

Financial summary – key metrics*

USD ($' 000)	Q2 2026	Q2 2025	Variance
Product revenue, net	**45,672**	**20,923**	**24,749**
Cost and operating expenses:			
Cost of sales	(20,468)	(24,445)	3,977
Research and development expenses, net	(27,898)	(27,430)	(468)
Selling, general and administrative expenses	(41,161)	(30,265)	(10,896)
Loss from operations	**(43,838)**	**(61,217)**	**17,379**
Total comprehensive loss	**(38,585)**	**(28,949)**	**(9,636)**

*Select metrics only; for full financials please refer to the Company's 10-Q filing

Cash, cash equivalents & marketable securities

$201.6M**

As of June 30, 2026

Capital base strengthened through five-year, interest-only credit facility

Autolus expects that its current and projected cash, cash equivalents and marketable securities, including the combined first and second tranches totaling $100M from the credit facility, will be sufficient to **fund the Company's operations into Q2 2028**.

**Cash, cash equivalents and marketable securities; excludes additional capital from credit facility financing which closed in July 2026.

Conclusion

Autolus is positioned for value creation

Obe-cel product franchise supports multiple growth opportunities

Initial Indication: Adult r/r B-ALL
Strong execution and market expansion

AUCATZYL®
obecabtagene autoleucel
suspension for IV infusion

1H 2026 Net Product Revenue

$71.9 million

- Increased FY 2026 guidance to $140-150m in net product revenue
- Significant opportunity to grow overall CAR T market in adult r/r B-ALL
- Physician interest to pursue investigator sponsored trials in 1st line ALL

Pipeline expansion opportunities grow future commercial potential in new indications

Product	Indication	Target	Preclinical	Phase 1	Phase 2/Pivotal	Approved
AUCATZYL®	Adult ALL	CD19				
obe-cel	Pediatric ALL	CD19				
obe-cel	Lupus Nephritis	CD19				
obe-cel	Progressive Multiple Sclerosis	CD19				

- Opportunity to establish a pipeline in a product with two pivotal Phase 2 clinical trials in lupus nephritis and pediatric ALL and a Phase 1 clinical trial in progressive MS
- Clinical data catalysts throughout 2027

Commercial and pipeline opportunities supported by proven manufacturing and product delivery capabilities and established authorized treatment centers

Autolus

Thank you